News – Page 469 – Endpoints News

#ESMO22: Trailing Roche’s Tecentriq, immune checkpoint therapies meet untreated liver cancer with mixed results

3 years ago

#ESMO22: Trodelvy's long-awaited survival data in breast cancer are finally in — and better than expected

3 years ago

#ESMO22: Outside liver cancer, Keytruda notches key win in neoadjuvant setting but flops in head and neck tumors

3 years ago

#ESMO22: Bristol Myers spells out kidney cancer flop for Opdivo/Yervoy combo — but can a triplet catch on?

3 years ago

#ESMO22: Mirati vs. Amgen: Scrappy KRAS G12C contender outperforms its giant rival in colorectal cancer

3 years ago

On the heels of unprompted EMA review of Covid drug, FDA schedules adcomm for potential EUA

3 years ago

New study reveals the extent to which drugmakers use condition-specific charities to induce spending on costly drugs

3 years ago

Genentech, Novartis re-up chronic hive campaign with celebrity comedian spokesperson

3 years ago

Kyowa Kirin bolsters campaign to close racial disparity gap in rare ‘lymphoma of the skin’

3 years ago

Form 483 reveals spore contamination at a South Korean manufacturing site last year

3 years ago

Integral Molecular's off-target protein binding array nabs first spot in FDA pilot to speed new drug development ...

3 years ago

Eight years later, FDA revises draft guidance on pediatric clinical pharmacology studies

3 years ago

Investor suit fueled by news articles over failed cancer drug ends in $24M settlement

3 years ago

Ionis, AstraZeneca going to FDA with PhIII data in hand; Glaukos touts double PhIII win in eye implant

3 years ago

Pacira looks to expand use of Exparel for pain relief following knee replacement surgery

3 years ago

Shooting for a heavily pre-treated niche cancer market, Bicycle reveals a 'mixed' data cut

3 years ago

'Conflicts of interest': SEC charges Perceptive Advisors over SPAC dealings, settles for $1.5M penalty

3 years ago

Tiny transcriptome biotech secures Series A to ramp up automated R&D efforts in race toward clinic

3 years ago

After blocking Grail acquisition, EU leaves Illumina with few good options

3 years ago

Following lukewarm launch and layoffs, Zealand Pharma is licensing out its diabetes drug to Novo Nordisk

3 years ago

Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin

3 years ago

Watch out Moderna: John Maraganore, ARCH and Beam are hatching a platform play 'to lead the future of RNA therapies'

3 years ago

A Rich Heyman biotech backed by a top Salk scientist is auctioned off for its dwindling cash reserves

3 years ago

Over $50M in federal funds are going to Virginia’s pharma manufacturing sector

3 years ago

First page Previous page 466 467 468469470 471 472 Next page Last page